Status:

NOT_YET_RECRUITING

The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

Lead Sponsor:

Zhejiang University

Conditions:

Cervical Spinal Stenosis

Thoracic Spinal Stenosis

Eligibility:

All Genders

65+ years

Phase:

PHASE2

Brief Summary

Postoperative delirium is a delirium that occurs within 7 days after surgery or before hospital discharge. It has been shown that combined POD can increase the incidence of postoperative pulmonary inf...

Eligibility Criteria

Inclusion

  • Elderly patients undergoing orthopedic surgery under general anesthesia
  • Inclusion criteria:
  • Age ≥ 65 years;
  • Patients who were to undergo elective orthopedic surgery under general anesthesia with tracheal intubation;
  • ASA class I-III;
  • Estimated duration of surgery ≥ 1 hour; (5) The patient himself/herself or his/her legal representative;
  • Informed consent from the patient or legal representative;
  • Proficiency in the use of Chinese language for communication.
  • Exclusion criteria:
  • Nasal cavity occupation, patients with fillers in the nose
  • Oxytocin allergy;
  • Patients with previous psychiatric and neurological disorders, such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia disease.
  • Goldson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, and so on;
  • Pregnant and lactating women
  • Patients with severe hepatic insufficiency (Child-Pugh class C);
  • patients with severe renal insufficiency (dialysis is required before surgery)
  • Severe heart failure (METS\<4);
  • Preoperative inability to communicate (coma or dementia);
  • Severe preoperative blindness, deafness, or inability to understand Mandarin to complete preoperative delirium screening;
  • Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery;
  • Patients who are scheduled for 2 surgeries within 7 days of surgery;
  • Patients with bone malignancy
  • Currently participating in other clinical trials.

Exclusion

    Key Trial Info

    Start Date :

    June 1 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    June 30 2026

    Estimated Enrollment :

    220 Patients enrolled

    Trial Details

    Trial ID

    NCT06945926

    Start Date

    June 1 2025

    End Date

    June 30 2026

    Last Update

    May 25 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China, 310000